[1] The Digitalis Investigation Group. N Engl J Med 1997;336:525-533 (Ensayo Clínico).

[2] Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-17 (Ensayo Clínico).

[3] Lawson DH, Gray J, Henry DA, Tilstone WJ: Continuous infusion of furosemida in refractory oedema. Br Med J 1978; 2: 476.

[4] Lahav M, Regev A, Ra’Anani P, Theodor E: Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 1992; 102: 725-31.

[5] Rybak LP: Pathophysiology of furosemoide ototxicity. J Otolaryngol 1982; 11: 127-33.

[6] Channer KS, McLean KA, Lawson-Matthew P, Richardson M: Combination diuretic treatment in severe heart failure: Randomized controlled trial. Br Heart J 1994; 71: 146-50 (Ensayo Clínico).

[7] Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552 (Ensayo Clínico).

[8] Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-57 (Ensayo Clínico).

[9] Packer M, O'Connor M, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New Engl J Med 1996;335:1107-14 (Ensayo Clínico).

[10] The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Eng J Med 1987; 316: 1429-1435 (Ensayo Clínico).

[11] The SOLVD investigators: Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Eng J Med 1991; 325: 293-302 (Ensayo Clínico).

[12] Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Eng J Med 1991; 325: 293-302 (Ensayo Clínico).

[13] Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Cuddy TE: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - results of the Survival and Ventricular Enlargement Trial. N Eng J Med 1992; 327: 669-677 (Ensayo Clínico).

[14] Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-7 (Ensayo Clínico).

[15] Pfeffer MA , McMurray JJ , Velazquez EJ , Rouleau JL , Køber L , Maggioni AP , Valsartan in Acute Myocardial Infarction Trial Investigators .Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906 (Ensayo Clínico).

[16] McMurray JJ , Ostergren J , Swedberg K , Granger CB , Held P , Michelson EL , Olofsson B , Yusuf S , Pfeffer MA ; CHARM Investigators and Committees . Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003 ;362:767-71 (Ensayo Clínico).

[17] Cohn JN , Tognoni G ; Valsartan Heart Failure Trial Investigators . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 ;345:1667-75 (Ensayo Clínico).

[18] Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55 (Ensayo Clínico).

[19] The CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999; 353: 9-13 (Ensayo Clínico).

[20] MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet 1999; 353: 2001-7 (Ensayo Clínico).

[21] The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. Eur Heart J 1997; 18: 736-753 (Guía de Práctica Clínica).

[22] Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure): Guidelines for the Evaluation and Management of Heart Failure. Circulation 1995; 92: 2764-2784 (Guía de Práctica Clínica).

[23] Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112:2426-35 (Ensayo Clínico).

[24] Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterona blocker, in patients with left ventricular dysfunction after myocardial infaction. N Engl J Med 2003; 348: 1308-21 (Ensayo Clínico).

[25] De Teresa E, Alzueta J, Jimenez-Navarro M: Profiling risk from arrhythmic or hemodynamic death. Am J Cardiol 2000; 86 (Suppl 9ª): 126K-132K (Revisión).

[26] De Teresa E. Muerte Súbita, Arritmias e Insuficiencia Cardiaca. En De Teresa E, Anguita M (Editores): Insuficiencia Cardiaca. Datos para el Debate (2ª edición). Editorial Médica Panamericana. Madrid, 2007 (Revisión).

[27] Flather MD , Shibata MC , Coats AJ , Van Veldhuisen DJ , Parkhomenko A , Borbola J , et al; SENIORS Investigators . Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 ;26:215-25 (Ensayo Clínico).

[28] Yusuf S , Pfeffer MA , Swedberg K , Granger CB , Held P , McMurray JJ , Michelson EL , Olofsson B , Ostergren J ; CHARM Investigators and Committees . Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-81 (Ensayo Clínico).

[29] Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al., Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-67 (Ensayo Clínico).